- Takeda estimated an operating income of 225.00 billion yen, which was below the projected 425.04 billion yen.
- The net income forecast was 58.00 billion yen, significantly lower than the 233.49 billion yen estimate.
- The company forecasted net sales of 4.35 trillion yen, slightly above the expected 4 trillion yen.
- For the fourth quarter, an operating loss of 10.07 billion yen was reported in comparison to a profit of 88.56 billion yen year on year.
- Net loss in Q4 stood at 3.02 billion yen, versus a profit of 31.13 billion yen year on year.
- Net sales for the fourth quarter were 1.05 trillion yen, up 9.9% year on year, and above the 878.94 billion yen estimate.
- Takeda’s annual results showed a 5.9% increase in net sales from 4.08 trillion yen to 4.26 trillion yen.
- On a scale of analyst recommendations, the company received 9 buys, 12 holds, and 0 sells.
A look at Takeda Pharmaceutical Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Looking at Takeda Pharmaceutical‘s outlook through the Smartkarma Smart Scores lens reveals a promising future ahead. With a strong Dividend score of 5, the company is well-positioned to provide attractive returns to its investors over the long term. Additionally, Takeda scores high in Value at 4, indicating that the company is perceived as undervalued compared to its intrinsic worth, presenting a significant investment opportunity.
While Takeda Pharmaceutical shows areas of strength in Dividend and Value, there are areas of improvement needed in Resilience and Growth, scoring 2 and 3 respectively. Despite these lower scores, their focus on core therapeutic areas like Oncology and Central Nervous System positions them well for future growth opportunities. With a balanced Momentum score of 3, Takeda Pharmaceutical is poised for steady progress in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
